The pharmaceutical giant has maintained full-year sales forecasts for vaccines and antiviral treatment, despite $8.1bn sales of Paxlovid pills performing better than expected. Overall sales of $27.74bn beat analysts' expectations.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.